Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Phase 3

• Conditions: Completely resected non-squamous non-small cell lung cancer patients (pathologic stage II-IIIA)

• Registration Number: JPRN-UMIN000006737
• Lead Sponsor: Steering committee for Randomized Phase III Study of Cisplatin + Pemetrexed and Cisplatin + Vinorelbine for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-11-17
• Study Completion: 2021-08-19
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 804

Inclusion Criteria

Not provided

Exclusion Criteria

1) Have active double cancer (synchronous double cancer and metachronous double cancer within a 5-year disease-free interval are defined as active double cancer; in situ uterocervical carcinoma judged to be curable by topical therapy, gastric/colorectal cancer resectable by endoscopy, and topically resectable active skin diseases, except malignant melanoma, are not included in active double cancer); however, a patient is eligible even if double primary NSCLC is observed in the resected lung. 2) Previously treated with cisplatin, pemetrexed or vinorelbine 3) Administration of folic acid or Vitamin B12 is not possible. 4) Serious post-operative complications (post-operative infections, suture failures, etc.) 5) Interstitial shadow considered to be clearly indicative of interstitial pneumonia on chest CT 6) Active infection 7) Requirement of continuous systemic administration (oral or intravenous) of steroid at a dose > 10 mg/day in the case of prednisolone, and the current use of an immunosuppressant; however, patients currently treated with oral steroid at a dose of 10 mg/day in case of prednisolone can be enrolled in the study. 8) Women who are currently pregnant or will not be compliant with a medically approved contraceptive regimen during and for 6 months after the treatment period and lactating women. Men who will not be compliant with a contraceptive regimen during and for 6 months after the treatment period. 9) History of serious drug hypersensitivity 10) Other serious complications 11) Others judged by the investigator to be unsuitable for the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified